Orexo（ORX）株式概要
スペシャリティファーマであるOrexo AB (publish)は、米国、欧州連合、英国、および国際的に医薬品およびデジタル療法を開発・販売している。 詳細
ORX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Orexo AB (publ) 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | SEK 21.00 |
| 52週高値 | SEK 43.40 |
| 52週安値 | SEK 14.38 |
| ベータ | 0.87 |
| 1ヶ月の変化 | 3.96% |
| 3ヶ月変化 | -19.08% |
| 1年変化 | 34.79% |
| 3年間の変化 | 108.33% |
| 5年間の変化 | -46.54% |
| IPOからの変化 | -76.67% |
最新ニュース
ナラティブの更新 • Apr 25
ORX: Higher Profit Margins And Lower P/E Assumptions Will Support Future Upside
Analysts have adjusted their view on Orexo with a modest shift in price expectations in SEK terms, citing slightly higher projected profit margins at 19.52% and a lower assumed future P/E of 124.01x as key factors behind the new price target. Valuation Changes Fair Value: SEK 38.0 remains unchanged compared with the previous SEK 38.ナラティブの更新 • Apr 09
ORX: Steady Margins And Elevated P/E Multiple Will Support Future Upside Potential
Analysts have kept their SEK price target for Orexo broadly steady, with only a marginal adjustment that reflects slightly revised views on long term profit margins and the future P/E multiple, while leaving fair value, discount rate, and revenue growth assumptions effectively unchanged. Valuation Changes Fair Value: SEK 38.0 per share, effectively unchanged from the previous SEK 38.Recent updates
ナラティブの更新 • Apr 25
ORX: Higher Profit Margins And Lower P/E Assumptions Will Support Future Upside
Analysts have adjusted their view on Orexo with a modest shift in price expectations in SEK terms, citing slightly higher projected profit margins at 19.52% and a lower assumed future P/E of 124.01x as key factors behind the new price target. Valuation Changes Fair Value: SEK 38.0 remains unchanged compared with the previous SEK 38.ナラティブの更新 • Apr 09
ORX: Steady Margins And Elevated P/E Multiple Will Support Future Upside Potential
Analysts have kept their SEK price target for Orexo broadly steady, with only a marginal adjustment that reflects slightly revised views on long term profit margins and the future P/E multiple, while leaving fair value, discount rate, and revenue growth assumptions effectively unchanged. Valuation Changes Fair Value: SEK 38.0 per share, effectively unchanged from the previous SEK 38.ナラティブの更新 • Mar 26
ORX: Stable Margins And High P/E Multiple Will Support Upside Potential
Analysts have kept their SEK fair value estimate for Orexo broadly unchanged at SEK38.0, reflecting only minor tweaks to long term margin and P/E assumptions rather than any shift in the core thesis. Valuation Changes Fair Value: SEK38.0 remains essentially unchanged compared with the prior SEK38 estimate.ナラティブの更新 • Mar 12
ORX: Future P/E Support Will Rely On Stable Margins
Analysts have kept their SEK fair value estimate for Orexo broadly unchanged at SEK 38.0. This reflects only minor tweaks to underlying assumptions, such as slightly higher modeled revenue growth and a marginally lower future P/E multiple. Valuation Changes Fair Value: SEK 38.0 per share, unchanged from the prior SEK 38 estimate.ナラティブの更新 • Feb 25
ORX: Future P E Multiple Will Rely On Sustained Margin Support
Analysts have raised their price target for Orexo to SEK 38, citing an assumed revenue growth rate of 35% and a projected future P/E of about 129, while forecast profit margins are expected to ease to around 19%. Valuation Changes Fair Value: SEK 38 is unchanged, with the updated estimate remaining at SEK 38.0. Discount Rate: 5.224% is unchanged between the previous and updated assumptions.ナラティブの更新 • Feb 06
ORX: Higher Required Return Will Still Support Very Large Future P E Multiple
Narrative Update Analysts have trimmed their price target on Orexo to US$38.00, reflecting slightly higher discount rate assumptions and a modestly lower profit margin outlook. They are still applying a very large forward P/E multiple that keeps the fair value estimate unchanged at US$38.00.ナラティブの更新 • Jan 22
ORX: Stable Assumptions And Elevated P/E Will Support Long Term Upside
Analysts have kept their fair value target for Orexo unchanged at $38.00, citing largely stable assumptions around the discount rate, revenue expectations, profit margin, and a very high forward P/E estimate. Valuation Changes Fair Value: Kept unchanged at SEK 38.00 per share, reflecting stable core assumptions.ナラティブの更新 • Jan 07
ORX: Revised Earnings Assumptions Will Shape Balanced Long Term Prospects
Analysts have raised their price target on Orexo from SEK 31 to SEK 38, citing a substantial revision to future P/E assumptions and significantly lower revenue growth expectations, while keeping profit margin and discount rate inputs broadly unchanged. Valuation Changes Fair Value Target: raised from SEK 31 to SEK 38, reflecting a higher indicated equity value per share.ナラティブの更新 • Dec 14
ORX: New Science Park Facilities Will Support Stronger Long Term Prospects
Analysts have modestly raised their price target on Orexo to $31.00, highlighting a slightly richer future earnings multiple that is expected to offset a small anticipated erosion in long term profit margins. What's in the News Relocating to new, modern premises in Uppsala Science Park to support the next phase of the company’s development and growth (Key Developments) New facilities include laboratories, cleanrooms, and flexible office spaces designed to strengthen research and development capabilities (Key Developments) Site designed with a clear sustainability profile, featuring energy and cost efficient solutions to reduce environmental impact (Key Developments) Move aims to foster greater collaboration and innovation with partners, academia, healthcare providers, and patients (Key Developments) Valuation Changes Fair Value: Unchanged at SEK 31.0 per share, indicating no revision to the central valuation estimate.ナラティブの更新 • Nov 28
ORX: New Facility Move And R&D Will Drive Future Performance
Analysts have updated their price target for Orexo to $31.00. They are maintaining their previous estimate, as underlying assumptions around revenue growth and discount rates remain largely unchanged.ナラティブの更新 • Nov 13
ORX: Future Profit Margin Gains And R&D Move To Support Outlook
Narrative Update on Orexo Analysts have maintained their fair value estimate for Orexo at $31.00, citing stable expectations for revenue growth and recent improvements in profit margin projections as key factors supporting their unchanged price target. What's in the News Orexo AB is relocating to modern premises in Uppsala Science Park to strengthen research and development, enhance collaboration, and promote sustainability within its operations (Key Developments).分析記事 • Nov 02
Why Investors Shouldn't Be Surprised By Orexo AB (publ)'s (STO:ORX) 28% Share Price Plunge
Orexo AB (publ) ( STO:ORX ) shares have retraced a considerable 28% in the last month, reversing a fair amount of their...ナラティブの更新 • Oct 30
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
Analysts have raised their price target for Orexo to $31.00 per share. This update reflects improving revenue growth forecasts and a slightly higher projected profit margin.ナラティブの更新 • Oct 16
Zubsolv Litigation Settlement And OX640 Progress Will Secure Stability
Analysts have raised their price target for Orexo from $21.50 to $31.00. This decision is based on updated valuation methodologies, even as growth and margin expectations have been slightly adjusted.分析記事 • Sep 16
There's No Escaping Orexo AB (publ)'s (STO:ORX) Muted Revenues Despite A 29% Share Price Rise
Orexo AB (publ) ( STO:ORX ) shareholders have had their patience rewarded with a 29% share price jump in the last...分析記事 • Jun 10
Orexo AB (publ) (STO:ORX) Shares Fly 32% But Investors Aren't Buying For Growth
Orexo AB (publ) ( STO:ORX ) shareholders have had their patience rewarded with a 32% share price jump in the last...分析記事 • May 09
Orexo AB (publ) (STO:ORX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Orexo AB (publ) ( STO:ORX ) investors will be delighted, with the company turning in some strong numbers with its...分析記事 • May 02
Shareholders May Not Be So Generous With Orexo AB (publ)'s (STO:ORX) CEO Compensation And Here's Why
Key Insights Orexo to hold its Annual General Meeting on 8th of May CEO Nikolaj Sorensen's total compensation includes...
新しいナラティブ • Apr 10
Zubsolv Litigation Settlement And OX640 Progress Will Secure Stability
Legal settlements and strategic changes stabilize revenue streams, enhancing future planning and financial clarity for Orexo.分析記事 • Dec 20
A Piece Of The Puzzle Missing From Orexo AB (publ)'s (STO:ORX) 105% Share Price Climb
Orexo AB (publ) ( STO:ORX ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Nov 05
Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Orexo AB (publ) ( STO:ORX ) share price has fared very poorly over the last month, falling by a substantial 26...分析記事 • Aug 02
Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Orexo AB (publ) ( STO:ORX ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Jul 20
Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
The analyst might have been a bit too bullish on Orexo AB (publ) ( STO:ORX ), given that the company fell short of...分析記事 • May 29
Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Orexo AB (publ) ( STO:ORX ) shares have been powering on, with a gain of 28% in the last...分析記事 • Apr 03
Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Orexo AB (publ)'s ( STO:ORX ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...分析記事 • Dec 09
We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...株主還元
| ORX | SE Pharmaceuticals | SE 市場 | |
|---|---|---|---|
| 7D | 11.7% | 1.2% | 2.9% |
| 1Y | 34.8% | -9.2% | 13.1% |
業界別リターン: ORX過去 1 年間で-9.2 % の収益を上げたSwedish Pharmaceuticals業界を上回りました。
リターン対市場: ORX過去 1 年間で13.1 % の収益を上げたSwedish市場を上回りました。
価格変動
| ORX volatility | |
|---|---|
| ORX Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.4% |
| 10% least volatile stocks in SE Market | 3.7% |
安定した株価: ORX 、 Swedish市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ORXの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1994 | 65 | Nikolaj Sorensen | www.orexo.com |
スペシャリティファーマであるOrexo AB (publish)は、米国、欧州連合、英国、および国際的に医薬品およびデジタル療法を開発・販売している。同社の製品には、オピオイド使用障害治療薬Zubsolv錠、がん患者の画期的疼痛治療薬Abstral、不眠症治療薬Edluarなどがある。また、オピオイド過剰摂取治療薬OX124、レスキュー薬およびオピオイド過剰摂取治療薬OX125、粉末エピネフリンによるアナフィラキシー治療薬OX640、子宮内膜症治療薬OX-MPIを開発中である。また、デジタル治療薬としては、うつ病治療薬deprexis、アルコール管理薬vorvida、オピオイド使用障害治療薬modiaがある。同社はアベラ・バイオサイエンスAB社とAmorphOX技術に基づく鼻腔用粉末ワクチンの開発に関する共同研究契約を結んでいる。Orexo AB（publ）は1994年に設立され、スウェーデンのウプサラに本社を置いている。
Orexo AB (publ) 基礎のまとめ
| ORX 基礎統計学 | |
|---|---|
| 時価総額 | SEK 733.35m |
| 収益（TTM） | -SEK 417.90m |
| 売上高(TTM) | SEK 17.80m |
41.2x
P/Sレシオ-1.8x
PER（株価収益率ORX は割高か？
公正価値と評価分析を参照収益と収入
| ORX 損益計算書（TTM） | |
|---|---|
| 収益 | SEK 17.80m |
| 売上原価 | SEK 10.30m |
| 売上総利益 | SEK 7.50m |
| その他の費用 | SEK 425.40m |
| 収益 | -SEK 417.90m |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 16, 2026
| 一株当たり利益（EPS） | -11.97 |
| グロス・マージン | 42.13% |
| 純利益率 | -2,347.75% |
| 有利子負債／自己資本比率 | 0% |
ORX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 19:27 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Orexo AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| null null | ABG Sundal Collier |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |